ReviewThe Journal of antibiotics2025
"Global divide in carbapenem resistance and hypervirulence of Klebsiella pneumonia: comparing trends in India and developed nations"- a comprehensive review.
Review in The Journal of antibiotics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Article
- Antimicrobial Consumption and Resistance Dynamics Across Healthcare Level: Global Evidence and Stewardship Implications.Pathogens (Basel, Switzerland) · 2026Review
- <p>Molecular medicine reports · 2026Review
- Validation of Hexaplex Recombinase Polymerase Amplification Assay for the Detection of Carbapenemase Genes in Klebsiella pneumoniae Isolates From Pediatric Inpatients.Journal of clinical laboratory analysis · 2026Article
- Prevalence, multidrug resistance patterns, and carbapenemase-encoding genes of carbapenemase-producingSAGE open medicine · 2026Review
- The dual threat of hypervirulent and multidrug-resistantFrontiers in microbiology · 2026Review
- Iron metabolism contributes to virulence by enhancing serum resistance in the emerging high-risk clone ST15 CRKP.Virulence · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global health problem of carbapenem-resistant and hypervirulent Klebsiella pneumoniae (CRKP) is exacerbated by the lack of effective treatments and increasing resistance. This study compares the clinical impact, resistance mechanisms, and prevalence of CR-hvKP in industrialized and emerging nations, analyzing 300 papers from national databases and selecting 70 for further examination. Treatment effectiveness, clinical outcomes, resistance mechanisms, and prevalence were assessed in the study, which concentrated on CRKP and hvKP strains that carried virulence genes (rmpA, aerobactin, yersiniabactin) and carbapenemase genes (blaKPC, blaNDM, blaOXA-12). With 25% of studies identifying blaOXA-48, 30% reporting blaKPC, and 45% tying blaNDM to resistance, analysis showed β-lactamase genes are mostly responsible for carbapenem resistance in Klebsiella pneumoniae strains. Resistance rates for CR-hvKP range from 4.4% to 100% in India, where the condition is disproportionately common. Clinical results are alarming: hospital-admitted patients had death rates ranging from 30% to 60% and morbidity rates as high as 90%. The study emphasizes how plasmid-mediated resistance, immune evasion mechanisms, and enhanced biofilm development contribute to the pathophysiology of CR-hvKP, making therapy more difficult. Urgent action is needed to battle CR-hvKP and lessen its catastrophic clinical impact, as it is more common in India than developed countries.
Indexed as
Identifiers
40461635What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.